Little is known about the immune microenvironment of OCCCs and its impact on outcomes. We studied the expression of a panel of immune response genes in OCCC to identify the presence and prognostic relevance of irGES in these tumours. Methods: Immune response gene profiling was performed on 84 FFPE OCCC samples with matched clinical outcomes, collected between 2003 -2016, using the nanoString nCounter PanCancer Immune Profiling Panel. Unsupervised hierarchical clustering analysis was performed and each sample underwent analysis for protein levels of PD-1, PD-L1, MMR and ARID1A via immunohistochemistry (IHC). Results: Total of 74/84 samples were successfully profiled. Median age at diagnosis was 53 yrs. 41 (55.4%) were stage 1, 7 (9.5%) stage 2, 24 (32.4%) Stage3, 2 (2.7%) stage 4. 64/74 (86.5%) of pts received adjuvant chemotherapy post debulking surgery with 38% recurrence rate (median PFS 27 months (m)). Median follow up was 36m. Based on irGES, 4 distinct molecular subgroups of OCCCs were identified. G1 was hallmarked by high NK cell markers/PD-1 expression, G2 by increased CTLA-4/PD-L1 expression, G3 by adhesion cell markers, and G4 by increased levels of pro -angiogenic genes. G1 was observed to have significantly poorer PFS (median PFS 20m vs 68m, p¼ 0.011) and a trend towards poorer OS when compared with G2/3/4 (median OS 38.8m vs undefined, p ¼ 0.0501). G4 carried the best prognosis (median PFS 108m vs 26m, p¼ 0.0515; median OS undefined, p¼ 0.0726). This difference in OS and PFS was reflected in stage 1 pts (p < 0.02 and <0.05; respectively) with a similar trend observed but not significant in non-stage 1 pts. Significant correlation was observed between gene and protein expression of tumour PD-1, tumour and stromal PD-L1, and tumour IL-6 using IHC (p < 0.0001 for all comparisons). 6 (8.1%) pts were MMR deficient with no significant association between ARID1A and MMR expression across each irGES. Conclusions: OCCCs are heterogeneous and can be classified into 4 molecular subgroups based on their irGES profiles with distinct clinicopathological characteristics and prognostic outcomes. If validated in larger datasets, these signatures may serve to inform a clinical trial.
939PD An increased ratio of cytotoxic to suppressive T cells after neoadjuvant chemotherapy (NACT) is prognostic in advanced ovarian cancer Background: If epithelial ovarian cancer (EOC) had a poor prognosis, more than 20% of patients (pts) can expected long remission. Few data are available on long term quality of life (QoL) in these pts and results reported were usually not compared to those of healthy controls. VIVROVAIRE was a large national case-control study comparing pts reported outcomes (PROs) among EOC pts without relapse within 3 years after first line treatment and a group of healthy women. Methods: Pts were recruited in 27 French centers and clinical characteristics were issued from medical charts. Controls were randomized from electoral lists. Pts and controls matched on age. They filled in a form including PROs questionnaires: QoL, neurotoxicity and fatigue (FACT/G, FACT/O, FACT/GOG-Ntx, FACT/F), anxiety and depression (HADS), sleep disturbance (ISI) and Physical activity (IPAQ). Results: 318 pairs were analysed (from 349 pts and 327 controls included). Median age: 65 (20-86), high level of education: 52% and 58%, respectively. Pts characteristics: FIGO stage I/II (49%), III/IV (47%) unknown (4%); major histology, serous (50%), endometrioid (16%), clear cells (8%), mucinous (4%). BRCA1/2 mutations (n ¼ 21; 15%), unknown (n ¼ 168). 99% of the pts had a surgery and 96% received platinum based chemotherapy, associated with antiangiogenic agent (14%) Interval from first line therapy: median 5 years [2 to 24]. Pts reported lower physical and functioning QoL scores (p ¼ 0.03 and p ¼ 0.0002), higher score of fatigue (p < 0.0001), and poorer quality of sleep (p ¼ 0.0003) than controls. No difference of scores of anxiety and depression was observed between the 2 groups. TOI score (related to ovarian cancer and treatment) and score of neurotoxicity were higher among patients (p < 0.0001); 26% of pts reported severe fatigue, more than 70% of the pts were concerned about digestive symptoms and severe neurotoxicity. Only 18% of the pts and controls had an active physical activity. Conclusions: Compared to healthy women, EOC pts presented poorer long term QoL, fatigue with important neurotoxicity and digestive symptoms. Physicians have to take in count of the late effects of treatments to help the pts to cope with the sequelae. Legal entity responsible for the study: Centre Franc¸ois Baclesse Funding: Fondation de France; Ligue Nationale Contre le Cancer Disclosure: All authors have declared no conflicts of interest. safety and efficacy of Nimotuzumab with concurrent cisplatin and RT in patients with Ca Cervix.
Methods:
In this open-label randomized controlled multicentric study 100 patients with histologically confirmed Ca Cervix were recruited over a 4 year period with an equal allocation of 1:1 for intervention (Standard arm-concurrent CTRT (Cisplatin 40mg/m2 weekly IV þRT) plus 200mg weekly BIOMAB IV (n ¼ 50) on same day of cisplatin infusion) vs. standard arm only (n ¼ 50). At 2 years data were available for 39 patients in the intervention arm and 35 patients in standard arm. The size of the lesion was documented using CT/PETCT at baseline. The response was analyzed using RECIST criteria at the following treatment every 3 months for subsequent 2 years. Toxicity was assessed using CTCAE v4 toxicity criteria.
Results: There were 74 evaluable patients at end of 2 years. The mean age was 49.66 10.2 years. The complete response following treatment was seen in 37.8% (BIOMAB arm) of patients at two years following treatment compared to 38.2% in standard arm. However, progressive disease was seen more in standard arm (52.9%) compared to BIOMAB arm (35.1%). Best overall response was seen in 64.9% patients in the intervention arm compared to 47.1% patients in the standard arm at two years following treatment which is significant. At 2 years 60% progressed on standard arm compared to 37.5% in the intervention arm. Background: VAN is a bi-specific human IgG1 antibody, simultaneously blocking two key angiogenic factors, Ang-2 and VEGF-A. VAN as a single agent showed an objective response rate (ORR) of 29% in bevacizumab-naïve PROC. The anti-PD-L1 agent, ATEZO demonstrated a 22% ORR in advanced OC. Preclinical data suggested additive antitumor activity of VAN when combined with antiÀPD-L1. Hence, treatment with VAN plus ATEZO has the potential to reverse pro-angiogenic and immunesuppressive signals, thereby resulting in improved clinical benefit. Methods: Eligible patients (pts) had PROC measurable by RECIST 1.1. Pts with history of bowel obstruction, > 2 prior lines of systemic chemotherapy, or previous treatments with VEGF-A inhibitors or agents targeting Ang/Tie2 receptor axis were ineligible. Pts received VAN 2000 mg and ATEZO 840 mg, each IV Q2W, until disease progression or unacceptable toxicity. Primary efficacy endpoint was ORR as per RECIST 1.1, with tumor assessments every 8 weeks.
Results: 17 pts with median age of 63 years (range 45-74) were treated. Serous histology was present in all pts, except one clear cell subtype. 4 pts (24%) achieved confirmed PR, 8 pts (47%) experienced SD and 4 (24%) had PD, while one patient was not evaluable. The achieved RECIST ORR of 24% remained unchanged when evaluated as per immune-related response criteria. 9/17 pts were evaluable for CA-125 per GCIG criteria; three and two achieved a response with and without normalization respectively. The current estimate of PFS rate @ 6 months is 65% (median follow-up: 162 days). The most common adverse events (AE) of any grade (G) were decreased appetite, diarrhea (41% each), asthenia and constipation (35% each). AEs ! G3 included abdominal pain, LFT increase, asthenia, dyspnea, health deterioration, hypertension, GI obstruction, GI perforation (GIP), subileus, lymphedema, pleuritis and tonsillitis (6% each). One AE of GIP and asthenia each were fatal. Conclusions: Our data suggest that VAN plus ATEZO does not improve upon monotherapy with VAN or ATEZO in PROC. The safety profile of this combination is consistent with reports for the single agents in this setting. Clinical trial identification: NCT01688206 Legal entity responsible for the study: 
